Strategic partnerships Potential sales opportunity with Mammoth Biosciences centers on expanding collaborations with pharmaceutical and biotechnology companies through their in vivo gene editing capabilities and proprietary ultracompact CRISPR systems. Target conversations around joint development, research collaborations, and manufacturing support aligned with Abu Dhabi DoH and M42 MoU initiatives.

Therapeutic pipeline Mammoth is building an in vivo gene editing therapeutics pipeline, including base editing and epigenetic editing. Sales focus could be on enabling tools, services, and regulatory-ready platforms for preclinical and translational research, as well as potential co-development or licensing deals for certain modalities.

Diagnostics expansion There is an opportunity to cross-sell diagnostic applications of Mammoth CRISPR technologies through partnerships like the nonexclusive license with VedaBio. Focus on enabling rapid, decentralized diagnostics solutions for rare and inherited diseases in collaboration with diagnostics companies and healthsystems.

Global manufacturing Abu Dhabi manufacturing initiatives and ongoing international collaboration signal demand for clinical research support and therapy manufacturing. Propose services around process development, GMP manufacturing readiness, and tech transfer packages for in vivo editing therapies in regional hubs.

IP and collaboration leverage Leverage Mammoth’s differentiated IP portfolio and high-profile leadership to position ancillary technology licenses, training, and consultancy around CRISPR modalities beyond double-stranded breaks. Explore co-development, data-sharing arrangements, and strategic partnerships to accelerate routes to clinical trials.